



<b>FORM PTO-1449</b>		<b>ATTY. DOCKET NO.</b> 30727.001 IP1	<b>SERIAL NO.</b> 09/518,501
<b>LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</b>  <i>#11</i> (Use several sheets if necessary)		<b>APPLICANT:</b> METABASIS THERAPEUTICS, INC.	
		<b>FILING DATE:</b> March 5, 1999	<b>GROUP:</b> 1991



U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
<i>TUM</i>	AA	3,018,302	01/23/62	Bielefeld, et al.	<i>260</i>	<i>461</i>	<i>1600/2900</i>
<i>TUM</i>	AB	5,157,027	10/20/92	Biller, et al.	<i>514</i>	<i>167</i>	—
<i>TUM</i>	AC	5,658,889	8/19/97	Gruber, et al.	<i>514</i>	<i>43</i>	—

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
<i>TUM</i>	AD	0 002 062 A1	30.05.79	EP (and English language Abstract)				
<i>TUM</i>	AE	0 072 531 A1	23.02.83	EP (and English language Abstract)				
<i>TUM</i>	AF	0 158 057 A	16.10.85	EP (U.K. English language translation)				
	AG	0 180 276 A1	28.12.88	EP				
	AH	0 261 283 A1	22.09.86	EP				
	AI	0 161 955 A1	21.11.85	EPO				
	AJ	0 338 372 A2	25.10.89	EPO				
	AK	0 353 692 A2	07.02.90	EPO				
	AL	0 481 214 B1	22.04.92	EPO				
	AM	492 738	30.06.70	CH (and English language Abstract)				
<i>✓</i>	AN	987,378	17.09.70	UK				

EXAMINER: <i>James M. [Signature]</i>	DATE CONSIDERED: <i>7/8/02</i>
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant	

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

## APPLICANT:

METABASIS THERAPEUTICS, INC.

## FILING DATE:

March 5, 1999

## GROUP:

1614

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO
sm	AO 35 12 781 A1	10.04.85	DE (and English language U.S. Patent No. 4,952,740)			
	AP 96/01267	18.01.96	WO			
	AQ 97/03679	06.02.97	WO			
	AR 98/09668	12.03.98	WO			
	AS 98/39342	11.09.98	WO			
	AT 98/39343	11.09.98	WO			
	AU 98/39344	11.09.98	WO			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

sm	AV	"Patent Abstracts of Japan," Vol. 1998, No. 1, 30 January 1998 & JP 09241284 A (Yamishata Koji, et al.; Nippon Soda Co. Ltd), 16 September 1997
	AW	DeLombaert, et al., "N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endoproteptidase (NEP, EC 3.4.24.11) Inhibitors, <u>J. Med. Chem.</u> 37: 498-511 (1994)
	AX	Edmunson, et al., "Cyclic Organophosphorus Compounds. Part 23. Configurational Assignments in the 4-Phenyl-1,3,2,5-dioxaphosphorinane Series. X-Ray Molecular Structure of <i>cis</i> -2-Benzylamino-4-phenyl-1,3,2-dioxaphosphorinane 2-Oxide," <u>J. Chem. Res. Synop.</u> , 5: 122-123 (1989)
	AY	Farquhar, et al., "5'-4-(Pivaloyloxy)-1, 3, 2-dioxaphosphorin an -2-yl-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FDUMP)" <u>J. Med. Chem.</u> 38:488-495 (1995)
	AZ	Farquhar, et al., "Biologically Reversible Phosphate-Protective Groups," <u>J. Pharm. Sci.</u> 72(3): 324-325 (1983)

EXAMINER:

Examiner

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

**LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S  
INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

ATTY. DOCKET NO.

30727.001 IP1

SERIAL NO.

09/518,501

APPLICANT:

METABASIS THERAPEUTICS, INC.

FILING DATE:

March 5, 1999

GROUP:

161A

RECEIVED  
MAR 07 2002  
TECH CENTER 1600/2900
**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)**

CU	BA	Farquhar, et al., "Synthesis and Biological Evaluation of 9-[5'-(2-Oxo-1,3,2-oxazaphosphorinan-2-yl)-β-D-arabinosyl]adenine and 9-[5'-(2-Oxo-1,3,2-dioxazaphosphorinan-2-yl)-β-D-arabinosyl]adenine: Potential Neutral Precursors of 9-[β-D-Arabinofuranosyl]adenine 5'-Monophosphate," <u>J. Med. Chem.</u> 28: 1358-1361 (1985)
	BB	Farquhar, et al., "Synthesis and Biological Evaluation of Neutral Derivatives of 5-Fluoro-2'-deoxyuridine 5'-Phosphate," <u>J. Med. Chem.</u> 26: 1153-1158 (1983)
	BC	Freed, et al., "Evidence For Acyloxymethyl Esters of Pyrimidine 5'-Deoxyribonucleotides as Extracellular Sources of Active 5'-Deoxyribonucleotides in Cultured Cells," <u>Biochem. Pharmac.</u> 38: 3193-3198 (1989)
	BD	Hillers, et al., "Analogues of pyrimidinemono- and polynucleotides. IV. Phosphates of 1-(1,4-dihydroxy-2-pentyl)thymine and 1-(1,3-dihydroxy-2-propyl) uracil." <u>Khim Geterotski Soedin</u> 5:678-683 (1978). Chem Abst. v 89 no 17; abst no 146864u
	BE	Hunston, et al., "Synthesis and Biological Properties of Some Cyclic Phosphotriesters Derived from 2'-Deoxy-5-fluorouridine," <u>J. Med. Chem.</u> 27: 440-444 (1984)
	BF	Kryuchkov, et al., <u>Izv. Akad. Nauk SSSR, Ser. Khim.</u> 6: 1201-1248 (1987)
	BG	Lok, et al., "Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection," <u>J. Antimicrob. Chemotherap.</u> 14: 93-99 (1984)
	BH	Ludeman, et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogues. 4. Preparation, Kinetic Studies, and Anticancer Screening of "Phenyl ketophosphamide" and Similar Compounds Related to the Cyclophosphamide Metabolite Aldophosphamide," <u>J. Med Chem.</u> 29, 716-727 (1986)
	BI	Meier, et al., "Cyclic Saligenyl Phosphotriesters of 2', 3'-Dideoxy-2', 3'-didehydrothymidine (d4T) – A New Pro-Nucleotide Approach," <u>Bioorg. Med. Chem. Lett.</u> 7: 99-104 (1997)
	BJ	Meyer, et al., "2"-O'-Acyl-6-thioinosine Cyclic 3', 5'-Phosphates as Prodrugs of Thioinosinic Acid," <u>J. Med. Chem.</u> 22: 811-815 (1979)
✓	BK	Neidlein, et al., "Mild Preparation of 1-Benzyloxyiminoalkylphosphonic Dichlorides: Application to the Synthesis of Cyclic Phosphonic Diesters and Cyclic Monoester Amides," <u>Heterocycles</u> 35: 1185-1203 (1993)


EXAMINER:

Examiner

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

<b>FORM PTO-1449</b>  <b>LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</b>  (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b> 30727.001 IP1	<b>SERIAL NO.</b> 09/518,501
	<b>APPLICANT:</b> METABASIS THERAPEUTICS, INC.	
	<b>FILING DATE:</b> March 5, 1999	<b>GROUP:</b> 1614



RECEIVED  
MAR 07 2002  
TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
BL	Nifant'ev, et al., "1,3,2, - Diazaphodsporinanes", <u>Zh. Obshch. Khim.</u> , Vol. 49, 1979, Pages 53-61.	
BM	Nifant'ev, et al., "Synthesis and Structure of Some Stable Phospholane-Phospholanes," <u>Phos. Sulfur &amp; Silicon</u> 113, 1-13 (1996)	
BN	Predvoditelev D. , et al., "Glycero-2-hydroxymethylene phosphates" <u>Journal of Organic Chemistry of the USSR (English Translation</u> 13:1489-1492 (1977))	
BO	Predvoditelev, D. et al., "Synthesis of lipids and their models on the basis of glycerol alkylene phosphites. V. Cyclic phosphatidylglycerol and phosphatidylhydroxyhomocholine" <u>Journal of Organic Chemistry of the USSR (English Translation</u> 17:1156-1165 (1981)	
BP	Shaw & Cundy, "Biological Screens of PMEA Prodrugs," <u>Pharm. Res.</u> 10 (Suppl) S-294 (1993)	
BQ	Shih, et al., "Preparation and Structures of 2-Dimethylamino-4-phenyl-1,3,2-dioxaphosphorinane-2-oxides," <u>Bull. Inst. Chem. Acad. Sin.</u> 41: 9-16 (1994)	
BR	Starrett, et al., "Synthesis, Oral Bioavailability Determination, and <i>in Vitro</i> Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)-ethyl]adenine (PMEA)," <u>J. Med. Chem.</u> 37: 1857-1864 (1994)	
BS	Yamanaka, et al., "Metabolic Studies on BMS-200475, a New Antiviral Comound Active against Hepatitis B Virus," <u>Antimicrob. Agents Chemoth.</u> 43, 190-193 (1999)	
BT	Zon, et al., "4 Cyclophosphamide Analogues," <u>Prog. Med. Chem.</u> 19: 205-246 (1982)	

<b>EXAMINER:</b> Examiner <i>[Signature]</i>	<b>DATE CONSIDERED:</b> 7/9/02 <i>[Signature]</i>
<b>EXAMINER:</b> Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant	

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)  
Approved for filing 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Application Number 09/518,501  
Filing Date March 3, 2000  
First Named Inventor Erion  
Group Art Unit 1624  
Examiner Name T. McKenzie  
Attorney Docket Number 030727.0013.CIP1

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)				

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AA	Coppi, et al., "Lewis Acid Mediated Condensation of Alkenols and Aldehydes. A Selective Synthesis of Tetrahydropyrans and Oxepanes," J. Org. Chem., Vol. 53, No. 4, 911-913 (1988)	
	AB	Lohr et al., "Targeted chemotherapy by intratumor injection of encapsulated cells engineered to produce CYP2B1, and ifosfamide activating cytochrome P450," Gene Therapy, 5, 1070-1078 (1988).	
	AC	Bijsterbosch, et al., "Disposition of the Acyclic Nucleoside Phosphonate (S)-9-(3-Hydroxy-2-Phosphonylmethoxypropyl)Adenine," Antimicrobial Agents and Chemotherapy, Vol. 42, p. 1146-1150 (May 1998).	
	AD	de Waziers, et al., "Cytochrome P 450 Isoenzymes, Epoxide Hydrolase and Glutathione Transferases in Rat and Human Hepatic and Extrahepatic Tissues <sup>1</sup> ," The Journal of Pharmacology and Experimental Therapeutics, Vol. 253, No.1, p. 387-394 (1989).	

Examiner Signature

Date Considered

2/12/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Patents are required to respond

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
and to a collection of information unless it contains a valid OMB control number

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

<b>Application Number</b>	09/518,501
<b>Filing Date</b>	March 5, 1999
<b>First Named Inventor</b>	Erion
<b>Group Art Unit</b>	1624
<b>Examiner Name</b>	T. McKenzie
<b>Attorney Docket Number</b>	030727.0013.CIP1

(use as many sheets as necessary)

Sheet	2	of	2
-------	---	----	---

RECEIVED  
MAR 07 2002  
TECH CENTER 1600/2900

## NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner  
Signature

Date  
Considered

2/13/03

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

ATTY. DOCUMENT NO.  
30727.0013.CIP1SERIAL NO.  
09/518,501LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT:  
METABASIS THERAPEUTICS, INC.FILING DATE:  
March 5, 1999GROUP:  
1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
JM	AA	3,018,302	01.23.62	Bielefeld, et al.			
	AB	5,157,027	10/20 92	Biller, et al.			
	AC	5,658,889	8/19/97	Gruber, et al.			

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
JM	AD	0 002 062 A	30.05.79	EP (Abstract)				
	AE	0 072 531 A	23.02.83	EP (Abstract)				
	AF	0 158 057 A	16.10.85	EP (Abstract)				
	AG	0 180 276	28.12.88	EP				
	AH	0 261 283	22.09.86	EP				
	AI	0 161 955 A	21.11.85	EPO				
	AJ	0 338 372 A	25.10.89	EPO				
	AK	0 353 692 A	07.02.90	EPO				
	AL	0 481 214 A	22.04.92	EPO				
	AM	492 738 A	30.06.70	CH				
	AN	16 93 219 A	17.09.70	DE (Abstract)				

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S  
INFORMATION DISCLOSURE STATEMENT

APPLICANT:

METABASIS THERAPEUTICS, INC.


FILING DATE:

March 5, 1999

GROUP:

1614

(Use several sheets if necessary)



## FOREIGN PATENT DOCUMENTS

EXAMINER & INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
TC	AO	35 12 781 A1	10.04.85	DE (and English language U.S. Patent No. 4,952,740)				
	AP	96/01267 A	18.01.96	WO				
	AQ	97/03679 A	06.02.97	WO				
	AR	98/09668 A	12.03.98	WO				
	AS	98/39342	11.09.98	WO				
	AT	98/39343	11.09.98	WO				
	AU	98/39344	11.09.98	WO				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

AV	"Patent Abstracts of Japan," Vol. 1998, No. 1, 30 January 1998 & JP 09 241284 A (Yamishata Koji; Nippon Soda Co. Ltd), 16 September 1997
AW	DeLombaert, et al., "N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endoproteptidase (NEP, EC 3.4.24.11) Inhibitors, <u>J. Med. Chem.</u> 37: 498-511 (1994)
AX	Edmunson, et al., "Cyclic Organophosphorus Compounds. Part 23. Configurational Assignments in the 4-Phenyl-1,3,2λ5-dioxaphosphorinane Series. X-Ray Molecular Structure of <i>cis</i> -2-Benzylamino-4-phenyl-1,3,2-dioxaphosphorinane 2-Oxide," <u>J. Chem. Res. Synop.</u> , 5: 122-123 (1989)
AY	Farquhar, et al., "5'-4-(Pivaloyloxy)-1, 3, 2-dioxaphosphorin an -2-yl]-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FDUMP)" <u>J. Med. Chem.</u> 38:488-495 (1995)
AZ	Farquhar, et al., "Biologically Reversible Phosphate-Protective Groups," <u>J. Pharm. Sci.</u> 72(3): 324 (1983)

EXAMINER:

Examiner

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance, and not considered. Include a copy of this form with next communication to applicant



LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

## APPLICANT:

METABASIS THERAPEUTICS, INC.

## FILING DATE:

March 5, 1999

## GROUP:

1614

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

BA	Farquhar, et al., "Synthesis and Biological Evaluation of 9-[5'-(2-Oxo-1,3,2-oxazaphosphorinan-2-yl)-β-D-arabinosyl]adenine and 9-[5'-(2-Oxo-1,3,2-dioxazaphosphorinan-2-yl)-β-D-arabinosyl]adenine: Potential Neutral Precursors of 9-[β-D-Arabinofuranosyl]adenine 5'-Monophosphate," <u>J. Med. Chem.</u> 28: 1358-1361 (1985)
BB	Farquhar, et al., "Synthesis and Biological Evaluation of Neutral Derivatives of 5-Fluoro-2'-deoxyuridine 5'-Phosphate," <u>J. Med. Chem.</u> 26: 1153-1158 (1983)
BC	Freed, et al., "Evidence For Acyloxymethyl Esters of Pyrimidine 5'-Deoxyribonucleotides as Extracellular Sources of Active 5'-Deoxyribonucleotides in Cultured Cells," <u>Biochem. Pharmac.</u> 38: 3193-3198 (1989)
BD	Hillers, et al., "Analogues of pyrimidinemono- and polynucleotides. IV. Phosphates of 1-(1,4-dihydroxy-2-pentyl)thymine and 1-(1,3-dihydroxy-2-propyl) uracil." <u>Khim Geterotski Soedin</u> 5:678-683 (1978). Chem Abst. v 89 no 17; abst no 146864a
BE	Hunston, et al., "Synthesis and Biological Properties of Some Cyclic Phosphotriesters Derived from 2'-Deoxy-5-fluorouridine," <u>J. Med. Chem.</u> 27: 440-444 (1984)
BF	Kryuchkov, et al., <u>Izv. Akad. Nauk SSSR, Ser. Khim.</u> 6: 1201-1248 (1987)
BG	Lok, et al., "Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection," <u>J. Antimicrob. Chemotherap.</u> 14: 93-99 (1984)
BH	Ludeman, et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogues. 4. Preparation, Kinetic Studies, and Anticancer Screening of "Phenyl ketophos phamide" and Similar Compounds Related to the Cyclophosphamide Metabolite Aldophosphamide," <u>J. Med Chem.</u> 29, 716-727 (1986)
BI	Meier, et al., "Cyclic Saligenyl Phosphotriesters of 2', 3'-Dideoxy-2', 3'-didehydrothymidine (d4T) – A New Pro-Nucleotide Approach," <u>Bioorg. Med. Chem. Lett.</u> 7: 99-104 (1977)
BJ	Meyer, et al., "2"-O'-Acyl-6-thioinosine Cyclic 3', 5'-Phosphates as Prodrugs of Thioinosinic Acid," <u>J. Med. Chem.</u> 22: 811-815 (1979)
BK	Neidlein, et al., "Mild Preparation of 1-Benzylxyiminoalkylphosphonic Dichlorides: Application to the Synthesis of Cyclic Phosphonic Diesters and Cyclic Monoester Amides," <u>Heterocycles</u> 35: 1185-1203 (1993)

EXAMINER:

Examiner

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S  
INFORMATION DISCLOSURE STATEMENT

## APPLICANT:

METABASIS THERAPEUTICS, INC.

## FILING DATE:

March 5, 1999

## GROUP:

1614

(Use several sheets if necessary)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

BL	Nifant'ev, et al., "1,3,2, - Diazaphosphorinanes", <u>Zh. Obshch. Khim.</u> , Vol. 49, No. 1, 1979, Pages 64-74 (and English version as translated in corresponding English language publication)
BM	Nifant'ev, et al., "Synthesis and Structure of Some Stable Phospholane-Phospholanes," <u>Phos. Sulfur &amp; Silicon</u> 113, 1-13 (1996)
BN	Predvoditelev D. , et al., "Glycero-2-hydroxymethylene phosphates" <u>Journal of Organic Chemistry of the USSR (English Translation 13:1489-1492 (1977))</u>
BO	Predvoditelev, D. et al., "Synthesis of lipids and their models on the basis of glycerol alkylene phosphites. V. Cyclic phosphatidylglycerol and phosphatidylhydroxyhomocholine" <u>Journal of Organic Chemistry of the USSR (English Translation 17:1156-1165 (1981))</u>
BP	Shaw & Cundy, "Biological Screens of PMEA Prodrugs," <u>Pharm. Res.</u> 10 (Suppl) S24 (1993)
BQ	Shih, et al., "Preparation and Structures of 2-Dimethylamino-4-phenyl-1,3,2-dioxaphosphorinane-2-oxides," <u>Bull. Inst. Chem. Acad. Sin.</u> , 41: 9-16 (1994)
BR	Starrett, et al., "Synthesis, Oral Bioavailability Determination, and <i>in Vitro</i> Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)-ethyl]adenine (PMEA)," <u>J. Med. Chem.</u> 37: 1957-1864 (1994)
BS	Yamanaka, et al., "Metabolic Studies on BMS-200475, a New Antiviral Compound Active against Hepatitis B Virus," <u>Antimicrob. Agents Chemoth.</u> 43, 190-193 (1999)
BT	Zon, et al., "4 Cyclophosphamide Analogues," <u>Prog. Med. Chem.</u> 19: 205-246 (1982)

EXAMINER:

Examiner

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant